<?xml version="1.0" encoding="UTF-8"?>
<svg height="724.45" width="532.5381976575001" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <text svg_rhmargin="102.103" x="76.272,81.588,85.127,89.558,92.802,95.902,99.003,102.103" y="21.089000000000055" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:7.97px;font-style:italic;font-weight:normal;">Cancers </text>
  <text x="104.096,108.081,112.066,116.051" y="21.089000000000055" svg_rhmargin="120.036" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:7.97px;font-style:NORMAL;font-weight:BOLD;">2019</text>
  <text svg_rhmargin="122.029" x="120.036,122.029" y="21.089000000000055" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:7.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="124.021,128.006" y="21.089000000000055" svg_rhmargin="131.991" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:7.97px;font-style:italic;font-weight:normal;">11</text>
  <text x="131.991,133.984,135.976,139.961,143.94600000000003,491.809,495.794,499.779,501.772,506.123,508.777,510.77,514.755" y="21.089000000000055" svg_rhmargin="518.74" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:7.97px;font-style:NORMAL;font-weight:normal;">, 47 24 of 27</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="55.95799999999997" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">15. </text>
  <text x="98.05,103.419,108.217,113.515,116.072,119.798,121.995,124.192,130.422,132.618,139.455,141.651,143.848,146.054,150.667,155.061,160.025,164.823,167.38,172.749,177.547,179.744,181.94,187.309,189.506,191.703,193.917,200.718,205.516,208.38,211.245,213.802,215.999,218.196,224.9,227.097,229.294,231.499,236.807,242.105,244.662,248.871,251.068,253.265,261.577,263.774,265.971,268.185,273.238,278.202,283.0,288.114,290.311,292.499,297.868,300.065,302.262,304.476,312.788,317.674,321.883,325.354,329.08,331.277,333.473,340.178,342.375,349.176,351.372,353.569,355.775,361.645,366.442,370.168,373.894,376.451,381.336,383.533,385.73,391.96,394.157,396.354,398.568,404.438,409.736,413.462,417.188,421.397,423.954,426.511,428.708,430.904,438.215,440.412,445.596,447.793,449.99,452.204,458.997,461.554,466.351,471.65,474.576,476.773,478.97,485.876,488.073,490.27,492.484,497.853,500.41,505.709,507.906,510.102,515.471,517.668" y="55.95799999999997" svg_rhmargin="519.865" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Louis, C.U.; Savoldo, B.; Dotti, G.; Pule, M.; Yvon, E.; Myers, G.D.; Rossig, C.; Russell, H.V.; Diouf, O.; Liu, E.;</text>
  <text x="98.05,102.431,105.413,107.763,112.336,114.997,117.284,120.384,127.499,132.822,135.804,138.465,141.446,146.961,155.037,160.031,163.644,165.994,170.566,174.627,177.609,180.27,185.437,188.099,191.08,196.16500000000002,198.516,203.089,208.411,213.999,216.35,219.011,224.005,229.328,234.413,237.458,240.44,244.821,248.433,256.509,258.85,261.896,266.469,269.45,273.831,276.181,281.175,284.221,286.571,290.632,295.954,298.616,306.691,311.072,314.685,317.346,321.407,323.757,328.33,333.653,336.635,339.296,344.381,348.762,354.085,356.435,359.883,364.264,368.325,372.705,378.202,381.183,386.177,389.625,392.67,398.167,403.161,407.038,409.7,412.681,415.343,420.51,424.89099999999996,427.241,432.847,435.198,439.259,443.64,446.301,448.962,452.84,455.191,457.852,463.17499999999995,465.525,471.022,475.595,478.576,481.238,485.618,490.941,493.923,497.801,500.151,507.779,510.44,513.422" y="68.87" svg_rhmargin="518.745" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with</text>
  <text svg_rhmargin="159.56" x="98.05,103.268,107.563,112.97,116.35,121.246,126.204,128.814,133.297,137.099,140.022,144.917,152.835,157.318,159.56" y="81.78200000000004" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">neuroblastoma. </text>
  <text svg_rhmargin="182.755" x="162.339,167.817,170.31,174.291,178.272,182.755" y="81.78200000000004" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Blood </text>
  <text x="184.997,189.48,193.963,198.447" y="81.78200000000004" svg_rhmargin="202.93" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2011</text>
  <text svg_rhmargin="205.171" x="202.929,205.171" y="81.78200000000004" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="207.412,211.895,216.378" y="81.78200000000004" svg_rhmargin="220.861" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">118</text>
  <text x="220.862,223.10399999999998,225.345,229.828,234.312,238.795,243.278,247.761,252.244,256.728,261.211,265.694,267.93600000000004,270.715,273.701,280.058,283.439,288.334,292.136,295.938,301.927,306.222,309.208" y="81.78200000000004" svg_rhmargin="312.194" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 6050–6056. [CrossRef]</text>
  <text x="76.535,81.018,85.501,87.74300000000001,98.05,103.572,106.98,111.914,119.452,124.712,126.97200000000001,129.213,135.622,137.881,143.403,145.663,147.923,150.173,155.695,160.214,165.737,168.367,172.696,174.956,177.197,182.719,184.979,187.239,189.48,195.002,199.521,203.091,205.721,209.553,214.814,217.07399999999998,219.315,227.865,230.124,235.647,237.906,240.166,242.407,250.623,254.952,260.212,265.237,267.497,269.738,275.261,277.52,279.78,282.03,289.134,292.966,295.913,300.911,305.24,308.647,313.673,315.933,318.174,321.183,323.443,329.48,331.74,334.0,336.241,342.649,347.909,352.428,357.688,362.714,364.974,367.215,375.43,377.69,384.098,386.357,388.617,390.858,398.369,402.888,406.458,410.977,416.237,418.352,423.287,425.54699999999997,427.788,434.82,437.079,439.339,441.589,446.334,449.281,453.8,457.37,460.271,462.531,464.772,470.81,473.069,475.329,477.579,485.786,490.305,495.33,500.59,504.919,507.83,510.09,512.331,515.34,517.6" y="94.69299999999998" svg_rhmargin="519.86" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">16. Brown, C.E.; Badie, B.; Barish, M.E.; Weng, L.; Ostberg, J.R.; Chang, W.C.; Naranjo, A.; Starr, R.; Wagner, J.;</text>
  <text x="97.602,105.905,109.447,112.056,117.041,122.26,125.183,127.42500000000001,129.657,136.014,138.256,140.498,142.739,147.034,149.957,152.198,156.682,159.291,161.533,164.303,169.782,172.391,177.286,181.77,185.751,188.674,191.283,196.349,198.958,201.881,206.866,209.108,213.591,218.81,224.288,226.521,231.228,235.711,238.697,242.992,245.915,250.9,253.142,258.038,261.024,263.256,266.278,271.756,276.24,280.723" y="107.60500000000002" svg_rhmargin="286.713" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Wright, C.; et al. Bioactivity and Safety of IL13R</text>
  <text x="286.713" y="107.60500000000002" svg_rhmargin="292.617" style="fill:#000000;font-family:MGUWOX+EURM10;font-size:8.97px;font-style:NORMAL;font-weight:normal;">α</text>
  <text x="292.617,297.1,300.086,306.076,310.37,315.849,318.458,321.838,326.133,330.114,333.037,337.332,342.81,345.043,351.401,356.619,359.228,367.146,371.441,374.982,377.591,381.572,383.814,390.79,396.008,398.931,401.541,406.526,410.821,416.03900000000004,418.272,424.262,428.556,432.538,436.832,442.221,445.144,450.04,453.582,455.823,462.18,469.12,473.604,479.037,481.27,486.76599999999996,489.008,495.365,499.66,502.269,504.878,508.68,510.913,513.522" y="107.60500000000002" svg_rhmargin="518.74" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">2-Redirected Chimeric Antigen Receptor CD8+ T Cells in</text>
  <text svg_rhmargin="248.973" x="98.05,103.466,107.949,110.872,113.481,117.776,122.994,125.918,129.72,131.961,139.439,142.048,144.971,150.189,152.431,158.421,162.716,166.697,172.104,175.645,179.026,183.32,188.539,191.462,193.704,200.545,203.154,205.763,210.659,215.617,218.227,222.71,226.512,229.435,234.33,242.248,246.731,248.97299999999998" y="120.51599999999996" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Patients with Recurrent Glioblastoma. </text>
  <text svg_rhmargin="315.735" x="251.75,257.731,260.223,262.716,267.701,269.94300000000004,272.722,278.703,282.684,287.669,291.319,294.807,298.295,300.536,306.517,310.005,313.493,315.735" y="120.51599999999996" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Clin. Cancer Res. </text>
  <text x="318.513,322.996,327.479,331.963" y="120.51599999999996" svg_rhmargin="336.446" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2015</text>
  <text svg_rhmargin="338.687" x="336.445,338.687" y="120.51599999999996" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="340.928,345.411" y="120.51599999999996" svg_rhmargin="349.894" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">21</text>
  <text x="349.895,352.137,354.378,358.861,363.345,367.828,372.311,376.794,381.277,385.761,390.244,394.727,396.969,399.748,402.734,409.091,412.472,417.367,421.169,424.971,430.96,435.255,438.241,441.227,443.468,446.454,451.87,457.277,462.235,470.717,475.012,480.491" y="120.51599999999996" svg_rhmargin="483.477" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 4062–4072. [CrossRef] [PubMed]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="133.428" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">17. </text>
  <text x="98.05,102.936,107.145,112.259,117.144,119.34100000000001,121.582,127.961,130.158,132.355,134.587,141.291,146.59,151.388,153.585,155.825,160.684,162.881,165.078,167.318,174.12,178.513,181.07,183.267,185.508,192.819,195.015,197.212,199.444,207.414,211.807,216.921,221.798,223.995,226.236,231.104,233.301,235.498,237.729,243.098,245.655,247.852,250.093,255.954,258.15,260.347,262.588,265.514,268.071,272.465,274.662,276.893,284.204,286.401,288.598,290.838,298.149,302.543,307.657,309.854,312.085,320.055,322.252,324.484,330.714,335.828,338.385,346.144,350.353,353.824,356.381,360.282,362.514,366.908,372.022,374.887,377.444,382.329,386.538,391.652,393.893,397.206,401.415,405.316,409.525,414.806,417.671,422.469,425.773,428.699,436.458,441.255,446.624,449.181,454.497,458.706,464.07500000000005,466.316,471.702,473.934,477.836,482.045,484.602,487.159,490.885,493.125,496.051,500.849,504.32,506.552,509.417,514.531" y="133.428" svg_rhmargin="518.74" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Feng, K.; Guo, Y.; Dai, H.; Wang, Y.; Li, X.; Jia, H.; Han, W. Chimeric antigen receptor-modiﬁed T cells for the</text>
  <text x="98.05,100.617,108.408,116.199,121.519,126.654,131.471,134.348,139.483,143.709,147.194,151.605,156.908,161.814,164.046,168.863,171.801,174.042,179.345,183.756,186.632,189.2,193.426,198.561,201.437,205.17800000000003,207.41,214.769,217.336,220.212,225.34699999999998,227.58,232.97,239.702,244.608,250.502,253.44,257.666,262.218,267.521,270.847,275.073,278.814,282.555,285.123,290.258,295.164,297.395,301.807,307.198,312.183,316.594,321.729,325.647,329.873,335.264,337.505,340.822,345.048,347.616,352.027,357.33,361.071,365.297,370.688,376.034,379.361,383.587,386.525,390.01,394.421,398.339,401.215,406.032,409.517,414.423,416.655,421.79,426.607,431.742,434.68,438.421,446.212,450.623,453.191,455.758,457.999,461.917,466.143,468.71,471.277,473.51,476.078,481.398,486.533,491.439,493.679,497.597,502.008,507.143,511.061,515.287,518.101" y="146.34000000000003" svg_rhmargin="520.307" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.</text>
  <text svg_rhmargin="167.181" x="97.799,102.784,106.434,108.926,111.168,113.947,119.928,124.411,126.904,131.889,135.87,138.112,143.097,145.59,148.083,151.571,153.812,158.797,162.447,164.939,167.18099999999998" y="159.25099999999998" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Sci. China Life Sci. </text>
  <text x="169.96,174.443,178.926,183.41" y="159.25099999999998" svg_rhmargin="187.893" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2016</text>
  <text svg_rhmargin="190.134" x="187.892,190.134" y="159.25099999999998" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="192.376,196.859" y="159.25099999999998" svg_rhmargin="201.342" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">59</text>
  <text x="201.342,203.584,205.825,210.308,214.792,219.275,223.758,228.241,232.724,237.208,239.45,242.229,245.215,251.572,254.952,259.848,263.65,267.451,273.441,277.736,280.722,283.70799999999997,285.949,288.935,294.35,299.757,304.716,313.198,317.493,322.971" y="159.25099999999998" svg_rhmargin="325.957" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 468–479. [CrossRef] [PubMed]</text>
  <text x="76.535,81.018,85.501,87.74300000000001,98.05,104.885,109.363,112.74,117.721,122.011,124.931,127.851,130.09,132.339,137.167,139.406,141.645,143.903,149.063,154.464,156.703,158.961,167.094,169.333,171.572,173.821,180.754,185.645,188.565,191.485,194.092,196.33100000000002,198.579,205.414,207.653,209.892,212.15,217.318,222.379,227.27,232.483,234.722,236.971,242.444,244.683,249.386,251.625,253.864,256.113,262.464,267.677,271.215,273.822,277.62,280.54,285.431,287.66999999999996,289.918,294.621,296.86,304.304,306.543,308.782,311.04,318.493,322.971,327.952,332.905,337.384,339.99,342.597,344.83599999999996,347.085,350.068,352.307,359.24,361.479,363.71799999999996,365.976,371.449,375.74,383.21,385.817,389.615,391.854,394.102,397.121,399.36,406.293,408.533,410.772,413.02,418.493,421.87,426.161,431.374,436.587,440.878,443.753,445.99199999999996,448.241,456.715,458.954,465.457,467.696,469.935,472.193,477.666,481.043,485.934,493.404,498.617,500.856,503.105,511.579,513.818,518.073" y="172.163" svg_rhmargin="520.312" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">18. Gargett, T.; Yu, W.; Dotti, G.; Yvon, E.S.; Christo, S.N.; Hayball, J.D.; Lewis, I.D.; Brenner, M.K.; Brown, M.P.</text>
  <text x="98.05,104.768,111.583,115.986,118.918,122.651,127.943,132.161,136.07,138.632,143.959,147.868,150.105,156.348,163.198,169.08,171.325,176.72199999999998,178.959,185.202,189.42,191.982,194.544,198.27700000000002,200.523,207.373,212.497,217.877,222.095,225.406,230.301,235.10899999999998,237.354,242.672,247.48,250.35,254.568,259.692,262.562,264.799,271.649,275.559,278.429,280.992,285.966,290.369,293.239,295.802,300.609,305.734,307.979,312.381,317.506,322.88599999999997,325.122,331.937,336.155,338.717,342.935,345.805,348.367,353.175,358.3,360.545,365.44,370.248,372.81,375.363,380.171,387.514,390.077,395.201,400.09700000000004,402.342,409.192,414.317,417.187,419.749,424.645,428.863,433.988,436.224,441.603,446.728,450.637,455.445,460.754,465.879,468.749,472.967,476.445,478.69,483.559,488.869,491.73900000000003,493.976,497.885,502.287,507.412,509.657,514.526" y="185.07399999999996" svg_rhmargin="518.744" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">GD2-speciﬁc CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be</text>
  <text svg_rhmargin="353.928" x="98.05,103.384,106.714,111.536,114.416,118.646,122.567,125.447,129.677,135.07299999999998,137.317,142.227,145.548,150.37,158.169,160.412,167.283,171.205,174.084,176.654,181.644,186.06,188.939,191.509,196.331,201.472,204.413,206.983,212.123,217.519,222.845,226.766,230.997,236.393,238.636,244.898,249.129,251.699,254.269,256.503,263.339,267.57,271.986,274.865,280.005,282.248,287.132,292.043,294.286,299.621,306.456,309.397,313.813,316.057,321.453,324.023,328.845,332.767,337.677,342.093,347.49,351.72,353.92800000000005" y="197.986" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Protected From Activation-induced Cell Death by PD-1 Blockade. </text>
  <text svg_rhmargin="394.638" x="356.705,365.042,368.964,371.419,373.627,376.409,381.805,386.221,389.657,392.43,394.63800000000003" y="197.986" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Mol. Ther. </text>
  <text x="397.414,401.897,406.38,410.864" y="197.986" svg_rhmargin="415.347" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2016</text>
  <text svg_rhmargin="417.554" x="415.346,417.55400000000003" y="197.986" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="419.796,424.212" y="197.986" svg_rhmargin="428.628" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">24</text>
  <text x="428.628,430.836,433.079,437.495,441.911,446.327,450.743,455.159,459.575,463.991,468.407,472.823,475.031,477.804,480.745,487.007,490.337,495.159,498.903,502.648,508.548,512.778,515.719" y="197.986" svg_rhmargin="518.66" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 1135–1149. [CrossRef]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="210.89800000000002" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">19. </text>
  <text x="98.05,104.893,110.013,117.78,121.993,127.367,129.566,131.818,139.128,141.327,143.526,145.777,151.152,154.626,159.024,166.36,168.92,173.133,177.03,179.229,181.472,186.67,188.869,193.487,195.686,197.88500000000002,200.137,207.455,211.668,216.559,221.933,226.147,228.346,230.589,238.91,241.109,243.30800000000002,245.568,251.444,256.247,261.111,265.324,268.799,271.666,275.396,280.198,285.309,287.50800000000004,289.76,295.996,298.195,300.394,302.646,309.357,314.476,318.874,323.272,325.832,328.031,330.283,337.126,339.325,341.524,343.776,350.487,354.701,358.175,363.066,367.279,372.398,374.59700000000004,376.849,383.086,385.285,387.48400000000004,389.735,395.11,397.669,402.973,405.172,407.415,412.79,414.989,417.188,419.44,426.248,430.646,435.536,440.656,445.458,450.428,454.826,457.02500000000003,459.277,466.191,468.39,470.589,472.84,479.684,483.413,488.533,493.335,498.138,501.612,504.172,506.37100000000004,508.623,515.466,517.665" y="210.89800000000002" svg_rhmargin="519.864" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Ahmed, N.; Brawley, V.S.; Hegde, M.; Robertson, C.; Ghazi, A.; Gerken, C.; Liu, E.; Dakhova, O.; Ashoori, A.;</text>
  <text x="98.05,104.534,109.528,112.976,118.564,122.945,125.899,128.186,132.182,139.297,141.584,143.871,148.736,153.116,156.098,160.095,164.667,167.329,169.616,177.664,185.273,190.788,198.863,203.436,208.75900000000001,212.756,218.344,223.84,226.493,232.081,236.461,240.074,248.15,252.723,255.38400000000001,259.381,266.359,269.816,274.809,282.437,285.419,290.74199999999996,294.738,299.823,304.396,308.457,311.438,316.432,320.045,324.032,330.141,334.522,338.583,342.963,348.46,351.441,356.435,360.048,364.044,368.61699999999996,372.614,375.659,383.269,388.857,394.966,399.539,402.585,406.581,409.627,414.428,419.925,424.306,428.366,431.028,436.561,440.62199999999996,444.618,451.102,456.425,459.087,467.162,471.543,475.156,477.817,481.878,485.875,492.99,498.313,501.294,503.956,509.041,513.421" y="223.80899999999997" svg_rhmargin="518.744" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Corder, A.; et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Speciﬁc Chimeric Antigen</text>
  <text svg_rhmargin="418.589" x="98.05,104.159,108.54,112.601,116.982,122.478,125.46,130.453,133.901,136.947,145.599,150.592,156.18,158.842,164.375,168.756,174.344,177.307,182.91299999999998,185.876,192.361,196.742,199.403,202.064,205.942,208.905,211.951,216.944,220.557,223.511,226.493,231.815,236.196,239.159,242.242,250.317,258.393,263.908,269.231,274.224,277.206,282.528,286.909,290.522,295.095,300.591,305.676,308.639,313.633,316.679,319.642,327.251,332.839,338.948,343.521,346.567,352.091,357.084,360.962,363.624,366.605,369.267,374.434,378.81500000000005,381.778,386.579,391.152,394.6,398.661,403.654,411.73,416.303,418.59" y="236.721" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Receptor-Modiﬁed T Cells for the Immunotherapy of HER2-Positive Sarcoma. </text>
  <text svg_rhmargin="480.13" x="423.527,426.573,428.85999999999996,431.822,437.922,440.465,443.007,448.092,450.37899999999996,455.318,462.433,467.518,471.24,475.301,477.844,480.131" y="236.721" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">J. Clin. Oncol. </text>
  <text x="485.068,489.551,494.034,498.518" y="236.721" svg_rhmargin="503.001" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2015</text>
  <text svg_rhmargin="505.287" x="503.001,505.28799999999995" y="236.721" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="508.429,513.002" y="236.721" svg_rhmargin="517.575" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">33</text>
  <text x="517.575" y="236.721" svg_rhmargin="519.861" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">,</text>
  <text x="97.602,102.085,106.568,111.052,115.535,120.018,124.501,128.984,133.468,137.951,140.19299999999998,142.972,145.958,152.315,155.695,160.591,164.393,168.195,174.184,178.479,181.465" y="249.63199999999995" svg_rhmargin="184.451" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">1688–1696. [CrossRef]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="262.544" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">20. </text>
  <text x="98.05,103.638,108.211,116.287,120.667,124.28,128.158,130.445,136.837,143.321,145.608,153.217,155.503,157.79,166.268,174.92,177.581,180.243,182.904,187.285,195.361,199.238,203.619,208.942,211.229,217.621,223.731,226.017,228.304,236.772,241.94,246.513,251.836,258.237,263.826,266.487,271.06,275.633,280.718,285.803,290.184,293.128,295.41499999999996,301.808,306.179,308.466,310.753,319.221,324.389,328.961,334.284,340.686,345.488,348.469,352.85,357.231,362.554,367.611,371.992,375.44,380.525,384.906,390.229,393.274,398.862,403.435,408.758,413.843,418.224,423.391,427.772,430.433,436.021,438.308,444.701,449.502,451.789,454.07599999999996,462.553,468.141,471.589,476.583,480.963,484.576,487.557,489.698,494.078,497.956,500.243,506.635,515.287,517.574" y="262.544" svg_rhmargin="519.86" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Lamers, C.H.; Willemsen, R.; van Elzakker, P.; van Steenbergen-Langeveld, S.; Broertjes, M.;</text>
  <text x="98.05,105.147,110.077,113.905,116.849,121.174,124.74,132.271,134.898,137.011,142.031,145.038,153.245,157.76,162.78,167.8,172.315,174.572,176.802,179.809,182.066,184.323,186.554,193.651,198.581,202.409,205.353,209.678,213.244,220.774,223.402,225.515,230.535,232.792,235.022,240.539,242.797,245.054,247.293,252.033,254.661,258.986,261.613,263.726,266.733,271.058,273.956,276.213,278.453,283.193,285.45,287.707,289.938,296.926,301.251,306.245,310.57,313.513,317.341,319.598,321.829,327.86,330.118,332.375,334.614,341.503,345.07,349.585,352.528,357.043,365.015,369.53,371.787,374.018,377.024,379.282,387.489,389.746,391.977,395.019,402.992,410.965,416.409,421.664,425.989,428.22,431.624,435.949,439.777,445.203,450.133,455.388,459.217,463.542,467.36999999999995,469.6,472.544,477.474,479.704,482.647,486.214,490.729,495.983,499.812,504.832,509.157,514.412" y="275.456" svg_rhmargin="518.737" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Oosterwijk-Wakka, J.; Oosterwijk, E.; Sleijfer, S.; Debets, R.; Gratama, J.W. Immune responses to transgene</text>
  <text svg_rhmargin="381.658" x="98.05,102.533,107.752,113.22999999999999,115.472,118.852,123.147,126.07,129.45,134.346,139.412,142.021,145.563,150.046,152.655,154.897,159.963,164.258,168.239,171.162,176.058,179.6,181.841,184.45,189.66799999999998,191.91,197.299,201.782,204.705,207.315,211.609,216.828,219.751,223.553,225.794,228.717,232.098,236.393,240.876,243.799,248.094,253.572,255.814,263.292,265.901,268.824,274.04200000000003,276.284,280.579,285.205,287.447,292.513,295.123,300.189,305.084,308.07,312.365,317.583,322.569,325.178,330.396,334.691,338.986,342.366,346.661,352.139,354.381,359.87699999999995,362.119,366.1,370.395,373.005,375.614,379.416,381.658" y="288.367" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">and retroviral vector in patients treated with ex vivo-engineered T cells. </text>
  <text svg_rhmargin="404.849" x="384.433,389.911,392.404,396.385,400.366,404.849" y="288.367" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Blood </text>
  <text x="407.09,411.573,416.056,420.54" y="288.367" svg_rhmargin="425.023" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2011</text>
  <text svg_rhmargin="427.265" x="425.023,427.26500000000004" y="288.367" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="429.506,433.989,438.472" y="288.367" svg_rhmargin="442.955" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">117</text>
  <text x="442.956,445.19800000000004,447.439,451.922,456.406,460.889,465.372,469.855,472.09700000000004,474.876,477.862,484.219,487.6,492.495,496.297,500.099,506.089,510.383,513.369" y="288.367" svg_rhmargin="516.355" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 72–82. [CrossRef]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="301.279" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">21. </text>
  <text x="98.05,103.457,107.696,112.121,115.006,117.891,121.821,124.03399999999999,126.263,133.016,135.228,140.635,142.848,145.061,147.299,154.662,159.087,163.512,167.265,169.47799999999998,171.716,178.601,180.814,186.725,188.938,191.15099999999998,193.389,201.761,206.186,211.523,215.275,217.488,219.726,228.098,230.311,235.541,237.754,239.96699999999998,242.205,246.807,251.639,255.135,257.71,262.631,265.206,269.631,274.781,276.994,279.233,286.083,288.295,295.18,297.393,299.606,301.844,306.49,311.322,316.659,319.234,323.473,328.624,330.83700000000005,333.075,341.447,343.66,349.934,352.147,354.36,356.598,361.943,364.519,368.758,372.51,376.935,379.148,381.378,388.13,390.343,392.55600000000004,394.794,401.069,406.219,410.458,417.016,419.22900000000004,421.468,428.353,430.565,432.778,435.017,440.919,446.07,450.495,455.327,457.54,459.778,464.681,466.894,469.107,471.345,476.752,480.992,485.992,488.567,493.718,497.957,500.17,502.408,507.815,510.028,515.435,517.648" y="301.279" svg_rhmargin="519.86" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Beatty, G.L.; Haas, A.R.; Maus, M.V.; Torigian, D.A.; Soulen, M.C.; Plesa, G.; Chew, A.; Zhao, Y.; Levine, B.L.;</text>
  <text x="97.701,104.816,107.478,112.535,116.916,119.578,125.166,129.738,132.025,135.729,140.53,142.817,151.469,153.755,156.042,160.486,164.867,167.849,171.553,176.126,178.787,181.074,188.253,196.905,201.286,205.163,210.148,213.129,218.452,222.833,225.494,228.156,233.479,236.524,240.402,245.898,250.279,254.34,257.001,262.534,266.59499999999997,270.308,274.369,279.692,282.353,290.429,294.81,298.422,301.084,305.145,308.848,313.421,318.744,321.726,324.387,329.472,333.853,339.176,342.88,346.337,350.718,354.778,359.159,364.656,367.637,372.631,376.24399999999997,379.947,388.023,394.132,401.732,408.848,411.893,416.274,421.597,426.682,429.343,434.666,439.047,443.428,446.876,451.256,456.844,460.549,466.155,469.868,473.929,478.3,480.962,483.623,487.501,491.214,493.876,499.198,504.786,510.301,514.362" y="314.19" svg_rhmargin="518.743" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Albelda, S.M.; et al. Mesothelin-speciﬁc chimeric antigen receptor mRNA-engineered T cells induce</text>
  <text svg_rhmargin="261.176" x="98.05,102.533,107.752,110.675,113.284,116.27,119.193,124.6,132.517,137.413,140.955,143.196,147.679,151.66,154.583,157.192,162.258,164.868,167.791,172.776,175.018,177.627,182.845,185.087,188.889,193.784,196.393,199.003,204.481,206.723,214.64,219.123,221.733,224.342,229.327,234.546,239.029,244.247,248.228,250.837,255.132,258.934,261.17600000000004" y="327.102" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">anti-tumor activity in solid malignancies. </text>
  <text svg_rhmargin="345.368" x="263.953,269.934,273.915,278.9,282.549,286.037,289.525,291.767,294.753,301.728,308.704,313.69,318.675,322.656,325.149,327.391,330.17,336.15,339.638,343.126,345.368" y="327.102" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Cancer Immunol. Res. </text>
  <text x="348.146,352.629,357.112,361.596" y="327.102" svg_rhmargin="366.079" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2014</text>
  <text svg_rhmargin="368.321" x="366.079,368.321" y="327.102" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="370.562" y="327.102" svg_rhmargin="375.045" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">2</text>
  <text x="375.045,377.28700000000003,379.528,384.011,388.495,392.978,397.461,401.944,406.427,410.911,413.153,415.932,418.918,425.275,428.655,433.551,437.353,441.154,447.144,451.439,454.425,457.411,459.652,462.638,468.054,473.46,478.419,486.901,491.196,496.674" y="327.102" svg_rhmargin="499.66" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 112–120. [CrossRef] [PubMed]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="340.014" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">22. </text>
  <text x="98.05,103.327,108.321,113.836,116.123,118.747,123.009,125.295,127.58200000000001,130.398,133.444,136.105,140.678,146.001,151.086,153.37300000000002,155.997,161.585,163.872,166.15900000000002,168.975,175.075,180.398,184.971,190.294,195.379,197.666,200.29,205.878,208.165,210.452,213.268,218.856,224.371,226.65800000000002,229.291,236.48,238.766,241.053,243.87,249.97,255.293,260.286,265.801,268.08799999999997,270.712,277.901,280.187,282.474,285.291,290.879,293.54,298.113,303.106,305.393,308.018,314.118,316.404,318.691,321.508,330.205,335.72,338.007,340.631,348.241,350.527,352.81399999999996,355.63,362.709,368.224,370.51099999999997,373.144,379.784,382.071,384.358,387.174,393.274,398.597,404.112,406.399,409.023,414.126,416.413,418.7,421.516,430.168,434.549,439.872,444.957,447.24399999999997,449.868,457.477,459.764,462.051,464.867,469.248,472.23,474.863,479.436,482.098,484.385,488.317,493.841,499.163,503.736,507.614,511.995,514.62" y="340.014" svg_rhmargin="519.193" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">You, F.; Jiang, L.; Zhang, B.; Lu, Q.; Zhou, Q.; Liao, X.; Wu, H.; Du, K.; Zhu, Y.; Meng, H.; et al. Phase 1</text>
  <text x="98.05,101.951,104.508,107.066,112.18,114.737,118.638,123.032,125.589,127.662,130.527,133.998,136.555,140.948,143.505,145.579,150.948,155.157,162.916,167.714,172.828,176.554,179.418,182.889,187.283,190.147,194.356,199.725,201.799,204.664,209.778,214.171,217.036,219.109,227.422,234.258,240.488,244.882,246.964,252.237,257.034,260.76,263.317,266.182,268.739,273.704,277.913,279.995,287.754,291.963,294.828,299.221,302.947,305.812,310.205,313.07,315.618,319.519,321.602,325.328,329.537,337.296,339.853,344.967,349.36,351.91700000000003,353.991,358.956,363.165,366.89,369.447,373.349,375.906,380.115,382.189,386.09,390.484,395.598,399.499,403.708,407.17900000000003,409.253,413.154,417.548,422.662,424.736,429.595,433.80400000000003,435.878,440.087,442.855,445.781,449.99,453.891,456.756,459.313,464.278,468.487,471.044,475.93,478.003,482.212,485.683,490.076,495.445,498.002,501.904,506.297,509.162,513.371" y="352.925" svg_rhmargin="518.74" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated</text>
  <text svg_rhmargin="375.702" x="98.05,103.018,108.013,110.242,118.175,123.08,128.57,131.184,136.62,140.923,146.412,148.65,155.64,160.868,163.797,166.412,169.404,177.903,184.893,191.262,195.754,197.983,201.972,207.201,209.815,217.748,222.052,225.601,228.215,232.204,234.441,238.933,244.162,247.091,249.706,254.701,259.004,264.233,266.461,269.848,274.152,278.141,282.444,287.844,290.773,295.678,299.227,301.464,304.393,307.942,312.434,317.663,321.472,326.962,332.37,336.359,340.663,346.152,348.389,353.896,356.125,360.114,364.418,367.032,369.646,373.456,375.702" y="365.837" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">by modiﬁed Anti-MUC1 chimeric antigen receptor transduced T cells. </text>
  <text svg_rhmargin="447.966" x="378.481,383.476,387.133,389.631,391.87699999999995,394.653,400.645,405.138,407.635,412.63,416.61899999999997,418.848,423.843,426.341,428.838,432.333,434.57,439.566,443.222,445.72,447.966" y="365.837" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Sci. China Life Sci. </text>
  <text x="450.741,455.224,459.707,464.191" y="365.837" svg_rhmargin="468.674" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2016</text>
  <text svg_rhmargin="470.919" x="468.673,470.919" y="365.837" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="473.154,477.646" y="365.837" svg_rhmargin="482.138" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">59</text>
  <text x="482.138,484.38399999999996,486.621,491.113,495.605,500.098,504.59,509.082,513.574,518.066" y="365.837" svg_rhmargin="520.312" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 386–397.</text>
  <text x="98.05,101.036,107.393,110.773,115.669,119.471,123.272,129.262,133.557,136.543,139.529,141.77,144.756,150.172,155.578,160.537,169.019,173.314,178.792" y="378.748" svg_rhmargin="181.778" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">[CrossRef] [PubMed]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="391.66" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">23. </text>
  <text x="98.05,104.15,109.473,114.046,119.369,124.454,126.741,129.054,135.538,137.825,140.112,142.471,150.784,155.357,160.68,165.765,168.052,170.374,176.475,178.761,181.048,183.398,188.675,193.248,198.571,203.656,205.943,208.256,214.356,216.643,218.93,221.289,229.602,234.175,239.498,244.583,246.87,249.192,257.844,260.131,262.41799999999995,264.768,270.356,273.017,275.304,277.617,282.419,284.705,286.99199999999996,289.351,294.939,297.601,299.888,302.201,307.304,309.591,311.878,314.228,320.328,325.651,330.224,335.546,340.631,342.91799999999995,345.241,351.35,353.637,355.924,358.274,364.374,367.035,372.029,377.352,382.437,384.724,387.037,393.137,395.423,397.71,400.07,408.383,412.764,415.425,417.712,420.035,426.135,428.421,430.70799999999997,433.058,437.86,443.182,447.563,452.886,455.173,457.486,460.532,462.818,465.10499999999996,467.464,471.845,474.82700000000006,477.141,481.713,484.375,486.662,489.661,495.185,500.508,505.081,508.959,513.34,515.662" y="391.66" svg_rhmargin="518.744" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Zhang, C.; Wang, Z.; Yang, Z.; Wang, M.; Li, S.; Li, Y.; Zhang, R.; Xiong, Z.; Wei, Z.; Shen, J.; et al. Phase I</text>
  <text svg_rhmargin="442.591" x="98.05,103.474,107.237,111.179,115.617,118.2,122.639,125.532,128.116,133.282,138.217,141.173,148.044,152.89,156.654,160.906,163.161,167.794,171.301,173.884,178.322,180.905,183.151,187.998,190.95399999999998,193.209,199.502,206.408,212.338,215.294,220.73600000000002,222.99,228.431,233.598,237.85,241.356,245.794,251.129,256.065,258.319,262.935,267.374,270.711,275.647,279.899,282.793,285.376,290.542,295.47799999999995,297.732,304.026,309.449,316.355,321.73400000000004,323.99,332.387,336.639,339.533,343.971,347.735,350.629,355.067,357.961,360.544,364.48499999999996,366.74,373.034,377.88,380.463,385.31,388.648,392.9,396.841,399.735,404.173,406.75600000000003,409.011,415.305,419.743,424.909,428.85,433.102,436.609,440.372,442.591" y="404.572" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. </text>
  <text svg_rhmargin="483.546" x="445.403,453.783,457.724,460.192,462.411,465.225,470.648,475.087,478.54,481.327,483.546" y="404.572" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Mol. Ther. </text>
  <text x="486.358,490.841,495.324,499.808" y="404.572" svg_rhmargin="504.291" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2017</text>
  <text svg_rhmargin="506.51" x="504.291,506.51" y="404.572" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="508.765,513.203" y="404.572" svg_rhmargin="517.641" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">25</text>
  <text x="517.642" y="404.572" svg_rhmargin="519.861" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">,</text>
  <text x="97.602,102.085,106.568,111.052,115.535,120.018,124.501,128.984,133.468,137.951,140.19299999999998,142.972,145.958,152.315,155.695,160.591,164.393,168.195,174.184,178.479,181.465,184.451,186.692,189.678,195.094,200.5,205.459,213.941,218.236,223.714" y="417.483" svg_rhmargin="226.7" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">1248–1258. [CrossRef] [PubMed]</text>
  <text x="76.535,81.018,85.501,87.74300000000001,98.05,104.488,108.922,111.813,116.247,118.464,120.707,125.363,127.58,133.867,136.084,138.30100000000002,140.553,145.971,151.319,154.662,159.592,164.026,166.24300000000002,168.487,174.41,176.627,183.526,185.743,187.96,190.213,198.602,202.539,208.826,213.668,217.171,225.001,229.435,233.372,238.303,240.52,242.763,248.181,250.398,252.615,254.868,262.911,267.345,272.506,277.436,279.65299999999996,281.897,287.315,289.532,292.485,294.702,296.919,299.162,307.551,312.393,317.235,320.738,323.318,328.479,333.41,335.627,337.879,345.922,348.139,350.356,352.6,357.956,362.797,365.378,370.539,373.43,375.647,377.899,384.665,386.882,392.806,395.023,397.24,399.483,405.921,411.083,415.516,418.86,423.107,425.324,427.568,431.771,433.988,440.852,443.069,445.286,447.538,452.974,458.135,462.977,466.48,471.641,473.858,476.101,484.49,486.707,488.924,491.167,499.556,503.99,506.207,508.46,515.43,517.647" y="430.395" svg_rhmargin="519.864" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">24. Katz, S.C.; Burga, R.A.; McCormack, E.; Wang, L.J.; Mooring, W.; Point, G.R.; Khare, P.D.; Thorn, M.; Ma, Q.;</text>
  <text x="98.05,102.852,105.833,110.406,113.067,118.39,123.475,127.856,133.179,135.466,138.721,144.309,146.596,150.848,153.135,155.422,159.18,163.561,166.543,169.798,174.371,177.033,179.32,185.136,190.66,195.982,200.555,204.433,208.814,212.07,215.152,218.399,226.008,230.389,235.885,240.458,243.44,246.101,250.162,253.418,256.5,264.575,272.651,278.166,283.489,288.482,291.464,296.787,301.167,304.78,309.353,314.849,319.93399999999997,323.181,326.227,331.22,334.833,338.089,346.741,351.121,354.103,358.676,362.554,365.535,370.108,373.986,378.367,382.245,385.5,390.302,393.283,398.798,404.386,409.471,412.718,417.711,420.757,424.013,427.095,432.418,435.399,439.012,443.585,446.63,453.746,457.358,460.34,464.72,468.333,470.994,475.567,478.228,481.485,487.969,493.292,495.953,504.029,508.41,512.022,514.684" y="443.306" svg_rhmargin="518.745" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Stainken, B.F.; et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric</text>
  <text svg_rhmargin="373.837" x="97.701,104.579,109.725,112.607,115.179,120.095,124.33,129.475,131.721,137.626,141.861,145.786,150.021,155.335,158.217,163.044,166.377,169.321,177.684,182.511,187.913,190.486,195.835,200.069,205.47099999999998,207.717,212.641,215.585,219.511,223.745,226.318,228.89100000000002,231.145,236.565,241.71,245.945,249.437,253.857,259.171,264.087,266.332,269.276,274.103,277.595,279.841,286.109,291.511,298.389,303.747,306.001,311.403,313.975,318.97,323.205,326.697,328.943,337.306,341.541,344.423,348.844,352.592,355.474,359.895,363.643,367.878,371.627,373.837" y="456.218" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Antigen Receptor-Modiﬁed T-cell Therapy for CEA+ Liver Metastases. </text>
  <text svg_rhmargin="439.82" x="376.635,382.532,384.99,387.447,392.363,394.573,397.376,403.273,407.198,412.113,415.712,419.151,422.59000000000003,424.835,430.732,434.171,437.61,439.82" y="456.218" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Clin. Cancer Res. </text>
  <text x="442.621,447.104,451.587,456.071" y="456.218" svg_rhmargin="460.554" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2015</text>
  <text svg_rhmargin="462.764" x="460.554,462.76399999999995" y="456.218" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="465.014,469.434" y="456.218" svg_rhmargin="473.854" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">21</text>
  <text x="473.855,476.065,478.32,482.74,487.161,491.581,496.001,500.422,504.842,509.263,513.683,518.104" y="456.218" svg_rhmargin="520.314" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 3149–3159.</text>
  <text x="98.05,101.036,107.393,110.773,115.669,119.471,123.272,129.262,133.557,136.543,139.529,141.77,144.756,150.172,155.578,160.537,169.019,173.314,178.792" y="469.13" svg_rhmargin="181.778" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">[CrossRef] [PubMed]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="482.041" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">25. </text>
  <text x="98.05,101.075,106.552,111.838,116.888,122.174,126.716,132.002,135.853,138.124,140.368,146.435,148.706,153.038,155.309,157.57999999999998,159.832,168.425,172.966,175.237,177.48,184.62,186.89,189.16099999999997,191.405,197.472,202.014,204.975,210.261,215.22,218.654,223.004,225.27499999999998,227.519,233.586,235.857,238.128,240.371,247.301,252.26,260.281,264.632,268.483,270.754,273.006,278.556,280.826,289.419,291.69,293.961,296.204,301.754,306.295,308.938,312.789,315.06,317.313,324.379,326.65,329.675,331.945,334.216,336.46,342.009,346.969,349.24,351.483,358.549,360.82,365.589,367.859,370.13,372.383,379.449,384.472,388.823,394.373,397.016,399.28700000000003,401.53,410.122,412.393,414.664,416.917,423.947,428.488,433.62,436.263,440.614,444.465,446.736,448.979,455.047,457.318,464.384,466.655,468.926,471.178,477.618,482.159,487.182,490.77,495.312,497.955,500.226,502.469,510.026,512.297,515.321,517.592" y="482.041" svg_rhmargin="519.863" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Junghans, R.P.; Ma, Q.; Rathore, R.; Gomes, E.M.; Bais, A.J.; Lo, A.S.; Abedi, M.; Davies, R.A.; Cabral, H.J.;</text>
  <text x="97.701,104.544,107.104,110.033,117.351,122.154,129.921,133.65,136.21,138.40900000000002,140.643,147.487,149.686,154.303,156.503,158.702,160.936,165.149,168.016,170.242,174.64,177.2,179.399,182.178,187.491,192.61,197.008,200.738,204.951,207.176,210.14,212.375,216.958,220.432,222.992,227.39,229.95,232.184,236.986,239.915,242.15,248.993,254.112,256.98,259.539,262.468,267.781,272.399,280.72,287.56300000000005,289.789,296.597,300.81,304.54,307.1,311.99,317.109,321.323,324.79699999999997,327.031,333.268,340.111,345.987,348.916,354.308,356.533,362.77,366.983,369.543,372.102,375.832,378.066,380.626,385.745,387.979,393.292,396.599,401.402,405.131,407.999,412.397,415.264,419.47700000000003,421.712,427.948,432.346,437.466,441.371,445.584,449.059,451.25800000000004,454.029,459.341,464.144,467.874,471.603,474.163,479.027,481.587,485.8,488.034,493.91,498.713,501.272,505.485,507.711,510.64,515.443" y="494.953" svg_rhmargin="518.917" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Al-Homsi, A.S.; et al. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for</text>
  <text svg_rhmargin="452.07" x="98.05,101.032,106.183,109.068,113.307,116.803,121.228,125.157,128.042,130.617,135.768,140.689,142.928,145.91,151.061,153.946,158.185,161.68,164.256,168.495,173.831,178.752,181.327,186.478,188.717,193.141,196.088,201.513,203.752,210.027,214.266,216.841,219.416,221.656,227.001,232.152,236.576,240.072,247.887,252.311,256.241,261.073,266.48,271.401,276.551,280.976,288.79,291.366,295.295,299.047,301.286,305.711,309.463,311.712,316.137,318.376,325.225,329.464,332.349,336.588,340.084,347.899,350.474,355.624,360.049,365.2,368.085,370.324,375.156,378.103,380.342,386.617,389.192,391.767,396.918,399.493,403.422,407.847,410.42199999999997,412.662,418.573,422.813,426.565,431.884,436.716,441.866,445.618,449.858,452.071" y="507.864" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. </text>
  <text svg_rhmargin="484.176" x="454.847,460.254,463.538,467.467,470.909,473.856,477.786,480.733,484.176" y="507.864" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Prostate </text>
  <text x="486.413,490.896,495.379,499.863" y="507.864" svg_rhmargin="504.346" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2016</text>
  <text svg_rhmargin="506.558" x="504.346,506.559" y="507.864" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="508.799,513.224" y="507.864" svg_rhmargin="517.649" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">76</text>
  <text x="517.649" y="507.864" svg_rhmargin="519.861" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">,</text>
  <text x="97.602,102.085,106.568,111.052,115.535,120.018,124.501,128.984,133.468,137.951,140.19299999999998,142.972,145.958,152.315,155.695,160.591,164.393,168.195,174.184,178.479,181.465,184.451,186.692,189.678,195.094,200.5,205.459,213.941,218.236,223.714" y="520.7760000000001" svg_rhmargin="226.7" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">1257–1270. [CrossRef] [PubMed]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="533.688" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">26. </text>
  <text x="98.05,102.833,107.406,112.729,117.814,120.475,122.762,127.737,130.783,133.069,138.657,140.943,143.23000000000002,149.568,154.369,157.351,161.924,165.802,171.124,178.752,181.413,185.474,190.559,192.846,197.812,204.296,206.582,208.869,215.216,220.731,223.392,227.773,231.651,236.224,238.511,243.485,250.464,252.75,255.037,261.374,270.026,275.02,278.477,283.562,288.135,293.458,295.745,300.71,309.362,311.648,318.764,321.05,323.337,329.684,335.208,340.192,343.805,346.786,351.167,354.121,356.40799999999996,361.383,368.462,370.748,373.03499999999997,379.373,388.024,392.597,398.112,401.99,404.277,409.252,417.904,420.19,425.632,427.918,430.205,436.543,439.588,445.103,450.426,454.807,457.094,462.068,468.553,470.839,478.448,480.73499999999996,485.71,491.234,496.228,500.105,503.983,506.645,511.702,514.364" y="533.688" svg_rhmargin="518.745" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Tanyi, J.L.; Stashwick, C.; Plesa, G.; Morgan, M.A.; Porter, D.; Maus, M.V.; June, C.H. Possible</text>
  <text x="98.05,104.496,109.46,117.489,122.953,127.499,131.09,134.054,142.082,146.437,151.729,154.693,159.239,161.885,164.112,170.558,175.613,178.577,183.541,188.597,191.242,196.534,200.88899999999998,203.116,209.19,213.545,216.191,220.546,225.092,228.947,233.302,235.538,240.311,245.367,250.658,256.213,259.641,264.605,272.633,276.988,279.216,281.862,287.154,289.381,293.92699999999996,296.163,301.655,306.201,309.165,311.81,316.165,321.457,324.421,326.648,334.231,336.877,339.841,345.133,347.36,353.433,357.788,361.825,367.307,370.899,374.326,378.681,383.973,386.937,389.173,396.32,401.457,406.003,409.594,412.24,416.786,422.078,424.305,430.751,435.297,440.588,444.625,448.98,452.571,454.799,461.872,464.9,467.864,472.219,475.81,478.038,482.811,486.239,490.594,495.14,498.104,506.132,510.487,515.779" y="546.5989999999999" svg_rhmargin="518.743" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Compartmental Cytokine Release Syndrome in a Patient with Recurrent Ovarian Cancer After Treatment</text>
  <text svg_rhmargin="253.367" x="97.602,106.075,108.684,111.608,116.82600000000001,119.068,127.55,131.845,135.646,140.542,143.465,148.684,152.979,155.588,158.197,163.415,166.401,169.324,173.807,177.188,182.173,186.468,189.391,193.686,199.16400000000002,201.406,207.763,214.739,220.729,223.714,229.21,231.452,237.81,242.105,244.714,247.323,251.125,253.367" y="559.511" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">With Mesothelin-targeted CAR-T Cells. </text>
  <text svg_rhmargin="310.526" x="256.144,259.13,261.372,263.613,266.599,273.575,280.551,285.536,290.521,294.502,297.488,301.971,305.459,308.284,310.526" y="559.511" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">J. Immunother. </text>
  <text x="313.304,317.787,322.27,326.754" y="559.511" svg_rhmargin="331.237" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2017</text>
  <text svg_rhmargin="333.478" x="331.236,333.478" y="559.511" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="335.72,340.203" y="559.511" svg_rhmargin="344.686" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">40</text>
  <text x="344.686,346.928,349.169,353.652,358.136,362.619,367.102,371.585,376.069,380.552,382.79400000000004,385.573,388.559,394.916,398.296,403.192,406.994,410.795,416.785,421.08,424.066,427.05199999999996,429.293,432.279,437.695,443.101,448.06,456.542,460.837,466.315" y="559.511" svg_rhmargin="469.301" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 104–107. [CrossRef] [PubMed]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="572.422" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">27. </text>
  <text x="98.05,103.638,107.086,112.08,119.707,125.03,127.31700000000001,130.206,136.691,138.977,144.565,146.852,149.139,152.348,159.464,162.125,164.786,169.359,173.932,179.52,183.901,189.224,191.511,194.4,201.479,203.765,206.052,209.262,214.064,217.045,221.618,225.231,228.175,230.46200000000002,233.352,239.461,241.748,244.035,247.244,255.567,259.948,265.271,270.356,272.643,275.523,281.111,283.397,285.68399999999997,288.894,297.217,301.789,306.874,312.197,316.578,319.532,321.81899999999996,324.699,327.745,330.031,336.141,338.427,340.714,343.924,351.524,356.097,359.709,364.282,369.605,371.745,376.739,379.02599999999995,381.915,389.031,391.317,393.604,396.814,404.002,407.88,410.861,415.919,420.3,423.748,428.833,431.12,434.009,437.055,439.341,445.451,447.737,450.024,453.234,458.822,461.483,466.056,471.379,475.439,480.762,485.335,488.783,494.371,496.65799999999996,499.548,508.199,510.486,515.287,517.574" y="572.422" svg_rhmargin="519.86" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Brown, C.E.; Alizadeh, D.; Starr, R.; Weng, L.; Wagner, J.R.; Naranjo, A.; Ostberg, J.R.; Blanchard, M.S.;</text>
  <text x="98.05,104.481,107.059,109.637,114.961,119.391,122.279,125.778,128.356,132.289,137.215,139.43,141.671,144.621,146.835,149.05,151.291,155.942,158.52,166.343,171.658,175.414,180.251,185.407,187.622,189.863,192.813,195.027,197.242,199.483,203.727,206.615,208.856,213.285,215.863,218.078,220.851,226.768,231.012,235.937,239.277,243.52,247.277,251.033,253.611,258.448,263.604,265.845,270.682,273.632,275.873,282.632,285.21,287.788,292.625,297.524,300.102,304.531,308.287,311.175,316.012,323.834,328.264,330.496,334.926,337.876,340.764,345.007,348.50600000000003,350.747,357.028,362.184,364.762,372.584,376.828,380.327,382.905,386.83799999999997,389.08,395.972,401.128,404.015,406.593,411.519,415.762,420.918,423.151,429.068,433.312,437.245,441.488,446.812,449.7,454.537,458.036,460.278,465.212,468.162,474.443,478.686,481.264,483.842,486.083,491.514,496.67,500.913,504.412,508.842,514.166,518.099" y="585.3340000000001" svg_rhmargin="520.314" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Kilpatrick, J.; Simpson, J.; et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.</text>
  <text svg_rhmargin="158.116" x="98.05,105.026,107.268,109.509,114.988,119.973,124.456,126.949,129.191,131.97,134.956,137.19799999999998,139.439,147.903,151.391,155.874,158.11599999999999" y="598.246" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">N. Engl. J. Med. </text>
  <text x="160.895,165.378,169.861,174.345" y="598.246" svg_rhmargin="178.828" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2016</text>
  <text svg_rhmargin="181.07" x="178.828,181.07" y="598.246" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="183.311,187.794,192.277" y="598.246" svg_rhmargin="196.76" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">375</text>
  <text x="196.761,199.003,201.244,205.727,210.211,214.694,219.177,223.66,228.143,232.627,237.11,241.593,243.83499999999998,246.614,249.6,255.957,259.337,264.233,268.035,271.837,277.826,282.121,285.107" y="598.246" svg_rhmargin="288.093" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 2561–2569. [CrossRef]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="611.157" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">28. </text>
  <text x="98.05,102.619,106.652,111.938,116.897,122.374,124.645,126.879,129.904,132.175,134.446,136.68,142.738,148.024,152.566,157.525,159.796,162.021,167.09,169.36,171.631,173.865,179.415,183.766,188.898,191.541,196.827,201.178,203.44899999999998,205.674,211.224,213.494,219.044,221.315,223.58599999999998,225.82,231.878,237.165,241.706,246.992,252.043,254.314,256.548,260.871,263.142,266.167,268.437,270.708,272.943,279.973,284.514,289.646,292.289,296.14,298.411,300.646,309.238,311.509,320.101,322.372,324.64300000000003,326.868,335.46,339.811,342.454,346.805,352.091,357.378,362.337,365.925,369.776,372.737,375.00800000000004,377.242,380.267,382.537,385.562,387.833,390.10400000000004,392.338,398.932,404.409,407.052,409.696,414.746,419.705,424.837,428.688,433.738,438.28,443.33,447.871,450.142,452.367,455.428,457.699,459.97,462.204,467.754,471.178,475.529,480.815,486.101,490.643,495.929,498.2,500.434,507.501,509.772,515.321,517.592" y="611.157" svg_rhmargin="519.863" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Tchou, J.; Zhao, Y.; Levine, B.L.; Zhang, P.J.; Davis, M.M.; Melenhorst, J.J.; Kulikovskaya, I.; Brennan, A.L.;</text>
  <text x="98.05,103.496,106.089,111.463,113.69099999999999,115.92,121.864,124.093,126.321,128.558,134.003,138.46,142.417,146.686,150.643,152.871,155.108,159.788,162.016,166.142,168.37,170.598,172.836,177.105,180.011,182.238,186.695,189.288,191.51600000000002,194.297,198.976,203.433,206.4,210.67,213.575,218.53099999999998,220.759,225.215,230.402,235.84799999999998,238.076,243.521,246.329,251.721,255.678,260.135,264.092,269.048,271.284,276.151,279.119,281.347,284.35,289.537,292.443,295.963,300.42,303.325,308.699,316.569,321.435,324.956,329.412,332.006,334.234,337.237,342.425,344.51,348.779,352.736,355.642,358.236,363.102,368.289,372.068,374.296,379.162,382.13,384.367,390.686,395.873,398.467,406.337,410.606,414.126,416.72,420.677,422.905,429.839,435.026,437.932,440.526,445.481,449.75,454.937,457.165,463.119,467.388,471.345,475.614,480.971,483.876,488.743,492.264,494.491,497.459,503.778,510.712,516.666" y="624.069" svg_rhmargin="519.634" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Liu, X.; Lacey, S.F.; et al. Safety and Efﬁcacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR)</text>
  <text svg_rhmargin="236.699" x="97.773,103.26899999999999,105.511,111.868,116.163,118.772,121.382,125.18400000000001,127.425,130.034,135.25199999999998,137.494,145.976,150.271,153.194,157.678,161.479,164.402,168.886,171.809,174.418,178.399,180.641,186.119,189.499,193.794,198.277,202.079,205.002,207.244,213.601,218.084,223.303,227.284,231.579,234.457,236.69899999999998" y="636.981" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">T Cells in Metastatic Breast Cancer. </text>
  <text svg_rhmargin="320.891" x="239.476,245.457,249.438,254.423,258.072,261.56,265.048,267.29,270.276,277.251,284.227,289.213,294.198,298.179,300.672,302.91400000000004,305.693,311.673,315.161,318.649,320.891" y="636.981" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Cancer Immunol. Res. </text>
  <text x="323.669,328.152,332.635,337.119" y="636.981" svg_rhmargin="341.602" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2017</text>
  <text svg_rhmargin="343.843" x="341.601,343.843" y="636.981" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="346.084" y="636.981" svg_rhmargin="350.567" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">5</text>
  <text x="350.568,352.81,355.051,359.534,364.018,368.501,372.984,377.467,381.951,386.434,390.917,395.4,397.642,400.421,403.407,409.764,413.145,418.04,421.842,425.644,431.633,435.928,438.914" y="636.981" svg_rhmargin="441.9" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 1152–1161. [CrossRef]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="649.892" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">29. </text>
  <text x="98.05,105.361,109.57,114.455,118.664,120.861,123.111,129.49,131.687,139.999,142.196,144.393,146.634,152.003,156.212,159.524,164.41,168.136,170.693,175.086,180.2,185.569,187.766,190.007,195.376,197.572,203.952,206.149,208.346,210.595,215.48,218.037,221.763,226.877,231.086,233.898,236.095,238.336,245.04,247.237,254.073,256.27,258.467,260.716,268.018,272.227,279.986,285.285,290.399,294.793,297.35,300.214,302.771,306.497,308.694,310.934,313.86,316.057,318.983,321.18,323.377,325.626,333.587,337.981,341.452,344.765,348.974,354.088,356.285,358.525,364.395,366.592,371.205,373.402,375.599,377.848,386.16,390.062,396.898,400.369,403.234,408.348,413.646,416.458,418.65500000000003,420.896,423.822,426.019,432.723,434.92,437.117,439.366,444.735,447.292,452.406,454.603,456.844,463.68,465.877,472.713,474.91,477.107,479.356,483.969,487.871,492.985,495.542,500.34,508.099,510.296,512.545,515.471,517.668" y="649.892" svg_rhmargin="519.865" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Hege, K.M.; Bergsland, E.K.; Fisher, G.A.; Nemunaitis, J.J.; Warren, R.S.; McArthur, J.G.; Lin, A.A.; Schlom, J.;</text>
  <text x="97.898,100.824,106.123,111.237,115.446,117.643,119.69,125.92,128.117,135.428,137.624,139.821,141.939,146.552,151.666,155.875,159.346,166.674,169.231,174.346,176.543,178.59,183.203,185.4,192.236,194.433,196.48,201.093,205.487,208.413,212.622,215.487,219.379,221.576,223.667,226.532,231.831,239.59,244.387,247.858,249.906,252.77,256.241,260.635,263.402,268.719,272.62,277.506,280.063,285.177,290.06300000000005,292.11,296.503,301.617,306.986,309.034,311.591,319.35,327.109,332.407,337.521,342.319,347.205,351.414,356.528,359.085,362.986,365.543,368.408,373.29400000000004,375.35,380.148,383.074,385.121,389.022,394.137,396.694,404.453,408.662,412.132,414.689,418.59000000000003,420.638,425.032,430.146,433.011,435.568,440.453,444.662,449.77599999999995,451.824,455.136,459.345,463.247,467.456,472.737,475.602,480.399,483.87,485.918,488.844,495.074,501.91,507.78,510.706,513.632" y="662.804" svg_rhmargin="519.018" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">June, C.H.; Sherwin, S.A. Safety, tumor trafﬁcking and immunogenicity of chimeric antigen receptor (CAR)-T</text>
  <text svg_rhmargin="273.263" x="98.05,102.031,106.326,108.935,111.544,115.346,117.588,121.39,126.778,131.073,135.054,137.664,143.088,147.069,149.311,152.297,157.192,160.734,162.976,167.809,174.784,181.626,184.612,189.095,193.578,195.82,198.429,203.647,205.889,209.87,214.766,217.375,222.271,225.651,229.946,233.927,236.85,241.333,243.942,246.184,250.165,254.648,259.867,263.848,268.143,271.021,273.26300000000003" y="675.715" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cells speciﬁc for TAG-72 in colorectal cancer. </text>
  <text svg_rhmargin="358.773" x="276.04,279.026,281.26800000000003,283.509,286.495,293.471,300.447,305.432,310.417,314.398,317.384,321.867,325.355,328.18,330.422,333.201,339.181,343.162,348.148,351.797,355.285,358.773" y="675.715" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">J. Immunother. Cancer </text>
  <text x="361.013,365.496,369.979,374.463" y="675.715" svg_rhmargin="378.946" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2017</text>
  <text svg_rhmargin="381.188" x="378.946,381.18800000000005" y="675.715" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="383.429" y="675.715" svg_rhmargin="387.912" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">5</text>
  <text x="387.912,390.154,392.395,396.878,401.362,403.60400000000004,406.383,409.369,415.726,419.106,424.002,427.804,431.605,437.595,441.89,444.876" y="675.715" svg_rhmargin="447.862" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 22. [CrossRef]</text>
  <text svg_rhmargin="87.743" x="76.535,81.018,85.501,87.74300000000001" y="688.627" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">30. </text>
  <text x="98.05,105.165,107.827,110.488,112.775,116.707,121.509,123.795,130.911,133.197,135.484,140.276,145.077,150.4,153.062,155.34900000000002,159.281,164.732,167.018,169.305,174.088,182.739,187.312,190.925,193.586,197.647,199.934,203.866,206.948,209.235,211.52200000000002,216.304,224.627,229.2,234.523,239.608,241.895,245.827,254.479,256.765,259.05199999999996,263.844,268.645,271.627,275.075,280.068,285.391,289.452,293.833,298.918,301.205,305.137,312.216,314.502,318.764,321.05,323.337,328.12,334.229,339.223,343.101,347.481,349.768,353.71,356.755,359.042,362.087,364.374,366.661,371.443,377.031,380.571,386.086,391.674,396.996,401.99,404.277,408.209,411.255,413.541,421.141,423.428,425.715,430.497,435.299,438.28,442.661,445.643,448.304,452.685,456.142,459.187,463.989,466.97,471.351,476.519,480.899,486.222,490.1,495.093,500.416,502.703,506.635,515.287,517.574" y="688.627" svg_rhmargin="519.86" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Ali, S.A.; Shi, V.; Maric, I.; Wang, M.; Stroncek, D.F.; Rose, J.J.; Brudno, J.N.; Stetler-Stevenson, M.;</text>
  <text x="98.05,103.135,107.516,110.177,115.765,123.841,128.414,133.737,136.024,138.511,143.312,145.599,152.714,155.0,157.287,159.893,167.503,172.076,177.398,181.276,185.657,190.98,193.267,195.754,201.342,203.628,210.607,212.893,215.18,217.795,222.176,225.158,227.645,232.218,234.879,237.166,240.687,246.293,248.781,252.842,257.222,259.884,262.545,266.423,268.911,273.291,278.011,283.507,286.955,291.336,295.214,299.091,301.753,307.076,312.161,314.648,319.221,324.544,327.032,331.605,336.927,339.909,342.57,345.616,351.204,354.249,358.31,362.691,365.352,368.013,370.501,378.577,383.15,386.131,391.646,395.259,399.832,402.813,405.475,410.468,415.791,418.279,422.851,428.174,431.156,433.817,438.902,443.283,448.606,451.093,455.154,460.477,463.138,471.214,475.595,479.207,481.869,485.93,488.417,492.99,498.313,501.294,503.956,509.041,513.422" y="701.539" svg_rhmargin="518.745" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Feldman, S.A.; Hansen, B.G.; et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen</text>
  <text svg_rhmargin="287.241" x="98.05,101.43,105.725,109.706,114.001,119.39,122.313,127.209,130.751,132.992,136.973,141.456,146.863,150.665,154.95999999999998,157.201,160.582,164.877,172.794,175.403,179.205,183.007,185.616,190.512,195.73,199.53199999999998,201.773,206.669,209.655,211.896,219.814,225.22,227.83,230.753,233.362,238.751,241.36,245.655,247.897,255.814,260.799,265.094,267.703,272.599,280.516,284.999,287.24100000000004" y="714.45" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">receptor cause remissions of multiple myeloma. </text>
  <text svg_rhmargin="310.434" x="290.018,295.496,297.989,301.97,305.951,310.434" y="714.45" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">Blood </text>
  <text x="312.676,317.159,321.642,326.126" y="714.45" svg_rhmargin="330.609" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:8.97px;font-style:NORMAL;font-weight:BOLD;">2016</text>
  <text svg_rhmargin="332.851" x="330.609,332.851" y="714.45" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="335.092,339.575,344.058" y="714.45" svg_rhmargin="348.541" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:8.97px;font-style:italic;font-weight:normal;">128</text>
  <text x="348.542,350.784,353.025,357.508,361.992,366.475,370.958,375.441,379.924,384.408,388.891,393.374,395.61600000000004,398.395,401.381,407.738,411.119,416.014,419.816,423.618,429.607,433.902,436.888" y="714.45" svg_rhmargin="439.874" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:8.97px;font-style:NORMAL;font-weight:normal;">, 1688–1700. [CrossRef]</text>
 </g>
</svg>
